Schwannomas are benign tumors that arise from the Schwann cells of the nerve sheath; they account for about 10% of all primary brain tumors. More than 90% of intracranial schwannomas are vestibular. Facial nerve schwannomas are in the minority, even among nonvestibular schwannomas; facial nerve schwannomas account for less than 2% of all intracranial schwannomas and less than 1% of intrapetrous tumors. Facial nerve schwannomas can occur along any segment of the nerve, often involving multiple segments; they have a predilection for the geniculate ganglion and the labyrinthine, tympanic, and mastoid segments. The diversity of tumor locations results in variable symptoms, including facial palsy, hearing loss, tinnitus, otalgia, hemifacial spasm, and vestibular symptoms. Because of the rarity of facial schwannomas and the variety of their clinical presentations, there is no universal consensus on an optimal management strategy. Many consider excision with nerve grafting to be the primary treatment, but this procedure cannot guarantee either maintenance of vestibulocochlear function or recovery of the facial nerve function to greater than House-Brackmann (HB) Grade III. Accordingly, observation with regular follow-up imaging is advocated for patients with good facial nerve function and hearing that are relatively preserved.

Clinical article

**Ju Hyung Moon, M.D.,1,3 Won Seok Chang, M.D.,1,2,4 Hyun Ho Jung, M.D.,1,2,4 Kyu Sung Lee, M.D., Ph.D.,1,3,4 Yong Gou Park, M.D., Ph.D.,1,2,4 and Jong Hee Chang, M.D., Ph.D.1-4**

1Department of Neurosurgery, 2Gamma Knife Center, 3Brain Tumor Center, and 4Brain Research Institute, Yonsei University Health System, Seoul, Republic of Korea

**Object.** The aim of this study was to evaluate the tumor control rate and functional outcomes after Gamma Knife surgery (GKS) among patients with facial nerve schwannoma.

**Methods.** The authors reviewed the radiological data and clinical records for 14 patients who had consecutively undergone GKS for a facial nerve schwannoma. Before GKS, 12 patients had facial palsy, 7 patients had hearing disturbance, and 5 patients had undergone partial or subtotal tumor resection. The mean and median tumor volumes were 3707 mm³ and 3000 mm³, respectively (range 117–10,100 mm³). The mean tumor margin dose was 13.2 Gy (range 12–15 Gy), and the mean maximum tumor dose was 26.4 Gy (range 24–30 Gy). The mean follow-up period was 80.7 months (range 2–170 months).

**Results.** Control of tumor growth was achieved in all 12 (100%) patients who were followed up for longer than 2 years. After GKS, facial nerve function improved in 2 patients, remained unchanged in 9 patients, and worsened in 3 patients. All patients who had had serviceable hearing at the preliminary examination maintained their hearing at a useful level after GKS. Other than mild tinnitus reported by 3 patients, no other major complications developed.

**Conclusions.** GKS for facial nerve schwannomas resulted in excellent tumor control rates and functional outcomes. GKS might be a good primary treatment option for patients with a small- to medium-sized facial nerve schwannoma when facial nerve function and hearing are relatively preserved.

(http://thejns.org/doi/abs/10.3171/2014.8.GKS141504)

**Key Words** • Gamma Knife surgery • radiosurgery • facial nerve • schwannoma • stereotactic radiosurgery

Abbreviations used in this paper: GKS = Gamma Knife surgery; HB = House-Brackmann; SRS = stereotactic radiosurgery.
Gamma Knife surgery for facial nerve schwannomas

Methods

Since 2000, a total of 14 patients with a facial nerve schwannoma have undergone GKS at Severance Hospital, Yonsei University College of Medicine, in Seoul. Of these 14 patients, 6 were male and 8 were female and ages ranged from 17 to 63 years (mean 36.9 years). For 5 patients, partial or subtotal tumor resection had been previously performed, and diagnosis was confirmed by microsurgical observation. For the other 9 patients, the diagnosis was based on imaging findings and neurological signs. Neurological evaluation for facial nerve function and hearing was performed by using the HB grading system and the Gardner-Robertson classification, respectively. At the time of GKS, facial palsy was classified as HB Grade I for 2 patients, Grade II for 7 patients, Grade III for 2 patients, Grade IV for 1 patient, Grade V for 1 patient, and Grade VI for 1 patient. Hearing was graded as Gardner-Robertson Class I for 7 patients, Class II for 1 patient, Class III for 2 patients, and Class V for 4 patients. Of the 5 patients who underwent partial or subtotal resection before GKS, 1 patient experienced decreased facial nerve function and hearing and 3 patients experienced a significant reduction in hearing after surgery. Symptoms other than facial motor function and hearing reduction included tinnitus, hemifacial spasm, facial numbness, lacrimation, dizziness, otorrhea, decreased taste, diplopia, and seizure. Neoplasms were located in various segments of the facial nerve and in most patients involved multiple segments. Most tumors involved the geniculate segment (10 patients; 71.4%), followed in frequency by the labyrinthine segment (7 patients; 50%), the internal auditory canal (7 patients; 50%), the cerebellopontine angle (7 patients; 50%), the tympanic segment (5 patients; 35.7%), and the mastoid segment (3 patients; 21.4%). Mean and median tumor volumes were 3707 mm³ and 3000 mm³, respectively (range 117–10,100 mm³) (Table 1).

Based on T1-weighted Gd-enhanced MRI and on T2-weighted MRI, GKS was performed using the Leksell Gamma Knife model B, C, or Perfexion (Elekta AB). GammaPlan software (Elekta AB) was used for dose planning. The mean tumor margin dose, set as the 50% isodose line, was 13.2 Gy (range 12–15 Gy), and the mean maximum tumor dose was 26.4 Gy (range 24–30 Gy). After GKS, patients were evaluated with regularly scheduled imaging and clinical assessments.

Results

The mean radiological and clinical follow-up period was 80.7 months (range 2–170 months). Follow-up lasted longer than 2 years for 12 (86%) patients, among whom 9 (64%) have been followed up for longer than 5 years and 4 (29%) for longer than 10 years.

Tumor Control

Of the 13 patients who were followed up for longer than 6 months, the 6-month follow-up images showed tumor enlargement in 6 patients, tumor stability in 3 patients, and tumor regression in 4 patients. Of the 12 patients who were followed up for longer than 2 years, the last follow-up images showed tumor regression in 7 patients and tumor stability in 5 patients; no tumor enlargement was found in any patient (Figs. 1 and 2). Of the 6 patients for whom tumor enlargement was seen at 6 months, tumor regression was seen on the last follow-up images for 5 patients (Fig. 3), and 1 patient was not evaluated because the total follow-up duration was less than 1 year. One patient in the study group was not evaluated after GKS because the postradiosurgical period was less than 6 months. Tumor control was achieved in all 12 (100%) patients who had been followed up for longer than 2 years (Table 2).

Functional Outcomes

After GKS, facial nerve function improved in 2 patients and worsened in 3 patients. An improvement in facial palsy, from HB Grade III to Grade II, was observed in one patient, and a remarkable improvement, from HB Grade V to Grade II, was observed in another patient. Soon after GKS, facial nerve function worsened in 3 patients, from HB Grade II to Grade IV. For all 3 patients with deteriorated facial nerve function, MRI performed at 6 months after GKS showed tumor expansion and a loss of central enhancement. For the other 9 patients, facial nerve function remained unchanged after GKS.

Hearing function generally remained unchanged. Hearing worsened in 1 patient, but the overall function was still serviceable. All patients who had had serviceable hearing at the preliminary examination maintained hearing at useful levels after GKS. No other major complications occurred, although 3 patients reported mild tinnitus (Table 3; Fig. 4).

Discussion

Facial nerve schwannomas are rare, benign tumors that can originate anywhere along the course of cranial nerve VII. Although advances in imaging techniques have made diagnosis and identification of tumor origin much easier, it can still be difficult to distinguish facial nerve schwannomas from other neoplasms, such as vestibular schwannomas and meningiomas, located in the cerebellopontine angle and the petrous area of the temporal bone. A good indicator suggestive of facial nerve schwannoma is involvement of the geniculate ganglion or the labyrinthine, tympanic, or mastoid segment of the facial nerve; an additional clue can be the presence of primary symptoms associated with facial nerve function, including progressive or repetitive hemifacial weakness. However, when they occur in the internal auditory canal or at the cerebellopontine angle, facial nerve schwannomas are often impossible to distinguish from vestibular schwannomas. Since 2000, a total of 14 patients with a facial nerve schwannoma have undergone GKS at Severance Hospital, Yonsei University College of Medicine, in Seoul. Of these 14 patients, 6 were male and 8 were female and ages ranged from 17 to 63 years (mean 36.9 years). For 5 patients, partial or subtotal tumor resection had been previously performed, and diagnosis was confirmed by microsurgical observation. For the other 9 patients, the diagnosis was based on imaging findings and neurological signs. Neurological evaluation for facial nerve function and hearing was performed by using the HB grading system and the Gardner-Robertson classification, respectively. At the time of GKS, facial palsy was classified as HB Grade I for 2 patients, Grade II for 7 patients, Grade III for 2 patients, Grade IV for 1 patient, Grade V for 1 patient, and Grade VI for 1 patient. Hearing was graded as Gardner-Robertson Class I for 7 patients, Class II for 1 patient, Class III for 2 patients, and Class V for 4 patients. Of the 5 patients who underwent partial or subtotal resection before GKS, 1 patient experienced decreased facial nerve function and hearing and 3 patients experienced a significant reduction in hearing after surgery. Symptoms other than facial motor function and hearing reduction included tinnitus, hemifacial spasm, facial numbness, lacrimation, dizziness, otorrhea, decreased taste, diplopia, and seizure. Neoplasms were located in various segments of the facial nerve and in most patients involved multiple segments. Most tumors involved the geniculate segment (10 patients; 71.4%), followed in frequency by the labyrinthine segment (7 patients; 50%), the internal auditory canal (7 patients; 50%), the cerebellopontine angle (7 patients; 50%), the tympanic segment (5 patients; 35.7%), and the mastoid segment (3 patients; 21.4%). Mean and median tumor volumes were 3707 mm³ and 3000 mm³, respectively (range 117–10,100 mm³) (Table 1).

Based on T1-weighted Gd-enhanced MRI and on T2-weighted MRI, GKS was performed using the Leksell Gamma Knife model B, C, or Perfexion (Elekta AB). GammaPlan software (Elekta AB) was used for dose planning. The mean tumor margin dose, set as the 50% isodose line, was 13.2 Gy (range 12–15 Gy), and the mean maximum tumor dose was 26.4 Gy (range 24–30 Gy). After GKS, patients were evaluated with regularly scheduled imaging and clinical assessments.

The mean radiological and clinical follow-up period was 80.7 months (range 2–170 months). Follow-up lasted longer than 2 years for 12 (86%) patients, among whom 9 (64%) have been followed up for longer than 5 years and 4 (29%) for longer than 10 years.

Tumor Control

Of the 13 patients who were followed up for longer than 6 months, the 6-month follow-up images showed tumor enlargement in 6 patients, tumor stability in 3 patients, and tumor regression in 4 patients. Of the 12 patients who were followed up for longer than 2 years, the last follow-up images showed tumor regression in 7 patients and tumor stability in 5 patients; no tumor enlargement was found in any patient (Figs. 1 and 2). Of the 6 patients for whom tumor enlargement was seen at 6 months, tumor regression was seen on the last follow-up images for 5 patients (Fig. 3), and 1 patient was not evaluated because the total follow-up duration was less than 1 year. One patient in the study group was not evaluated after GKS because the postradiosurgical period was less than 6 months. Tumor control was achieved in all 12 (100%) patients who had been followed up for longer than 2 years (Table 2).

Functional Outcomes

After GKS, facial nerve function improved in 2 patients and worsened in 3 patients. An improvement in facial palsy, from HB Grade III to Grade II, was observed in one patient, and a remarkable improvement, from HB Grade V to Grade II, was observed in another patient. Soon after GKS, facial nerve function worsened in 3 patients, from HB Grade II to Grade IV. For all 3 patients with deteriorated facial nerve function, MRI performed at 6 months after GKS showed tumor expansion and a loss of central enhancement. For the other 9 patients, facial nerve function remained unchanged after GKS.

Hearing function generally remained unchanged. Hearing worsened in 1 patient, but the overall function was still serviceable. All patients who had had serviceable hearing at the preliminary examination maintained hearing at useful levels after GKS. No other major complications occurred, although 3 patients reported mild tinnitus (Table 3; Fig. 4).

Discussion

Facial nerve schwannomas are rare, benign tumors that can originate anywhere along the course of cranial nerve VII. Although advances in imaging techniques have made diagnosis and identification of tumor origin much easier, it can still be difficult to distinguish facial nerve schwannomas from other neoplasms, such as vestibular schwannomas and meningiomas, located in the cerebellopontine angle and the petrous area of the temporal bone. A good indicator suggestive of facial nerve schwannoma is involvement of the geniculate ganglion or the labyrinthine, tympanic, or mastoid segment of the facial nerve; an additional clue can be the presence of primary symptoms associated with facial nerve function, including progressive or repetitive hemifacial weakness. However, when they occur in the internal auditory canal or at the cerebellopontine angle, facial nerve schwannomas are often impossible to distinguish from vestibular schwannomas. In the series reported here, the preoperative diagnosis was preferentially based on MR imaging. For most patients, the geniculate ganglion or the labyrinthine segment was involved, and for 2 patients, disease was restricted to the cerebellopontine angle and the internal auditory canal. For these 2 patients whose tumors were impossible to distinguish from vestibular schwannomas, the diagnoses were confirmed by microsurgical observation. For 12 (85.7%) patients, the presence of facial weakness, with or without hearing loss, helped with diagnosis.
Management strategies for patients with facial nerve schwannomas include observation, resection, and radiosurgery. Traditionally, complete excision with facial nerve reconstruction had been considered the treatment of choice. Because most tumors engulf the facial nerve, it is almost inevitably sacrificed during surgery; facial nerve reconstruction, by use of end-to-end anastomosis or nerve grafting, is usually necessary. For patients who undergo tumor excision with nerve reconstruction, postoperative facial palsies unavoidably develop, and most patients do not recover facial nerve function better than HB Grade III.6,10,33 Therefore, approaches that favor facial nerve preservation, such as observation, partial or subtotal removal, bony decompression, fascicle preservation surgery, and SRS, are advocated for patients who have good facial nerve function before treatment.1,33 Observation could be a good management option, particularly for elderly patients or those with severe concurrent medical conditions;17 but interven-

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Patient Age (yrs), Sex</th>
<th>Symptoms</th>
<th>Prior Treatment</th>
<th>Tumor Location</th>
<th>Tumor Volume (mm³)</th>
<th>Radiation Dose (Gy)</th>
<th>Facial Function (HB grade)</th>
<th>Hearing (GR class)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>32, M</td>
<td>facial palsy, otalgia</td>
<td>none</td>
<td>GG, MF, TS</td>
<td>10,100</td>
<td>30 15</td>
<td>VI</td>
<td>II</td>
</tr>
<tr>
<td>2</td>
<td>46, F</td>
<td>facial palsy, hemifacial spasm, facial numbness</td>
<td>none</td>
<td>GG, MF, TS</td>
<td>2600</td>
<td>30 15</td>
<td>II</td>
<td>I</td>
</tr>
<tr>
<td>3</td>
<td>63, F</td>
<td>tinnitus, hypoacusis</td>
<td>none</td>
<td>CPA, IAC, LS, GG, MF</td>
<td>6700</td>
<td>27 13.5</td>
<td>I</td>
<td>V</td>
</tr>
<tr>
<td>4</td>
<td>36, F</td>
<td>facial palsy, hemifacial spasm, facial numbness</td>
<td>none</td>
<td>LS, GG</td>
<td>532</td>
<td>26 13</td>
<td>II</td>
<td>I</td>
</tr>
<tr>
<td>5</td>
<td>55, F</td>
<td>facial palsy, hypoacusis, tinnitus</td>
<td>none</td>
<td>LS</td>
<td>153</td>
<td>25 12.5</td>
<td>III</td>
<td>III</td>
</tr>
<tr>
<td>6</td>
<td>33, M</td>
<td>facial palsy, lacrimation</td>
<td>none</td>
<td>GG</td>
<td>117</td>
<td>26 13</td>
<td>II</td>
<td>I</td>
</tr>
<tr>
<td>7</td>
<td>36, F</td>
<td>hypoacusis, facial numbness</td>
<td>subtotal resection</td>
<td>CPA, IAC</td>
<td>3200</td>
<td>26 13</td>
<td>I</td>
<td>V†</td>
</tr>
<tr>
<td>8</td>
<td>30, M</td>
<td>facial palsy, hypoacusis, hemifacial spasm</td>
<td>subtotal resection</td>
<td>CPA, IAC</td>
<td>367</td>
<td>26 13</td>
<td>IV†</td>
<td>V†</td>
</tr>
<tr>
<td>9</td>
<td>30, M</td>
<td>hypoacusis, decreased taste, ataxia, diplopia</td>
<td>subtotal resection</td>
<td>CPA, IAC, LS</td>
<td>2500</td>
<td>26 13</td>
<td>II</td>
<td>V†</td>
</tr>
<tr>
<td>10</td>
<td>30, M</td>
<td>tinnitus, dizziness</td>
<td>none</td>
<td>CPA, IAC, LS, GG, MF</td>
<td>6600</td>
<td>26 13</td>
<td>II</td>
<td>I</td>
</tr>
<tr>
<td>11</td>
<td>52, F</td>
<td>facial palsy</td>
<td>none</td>
<td>GG, TS, MS</td>
<td>573</td>
<td>28 14</td>
<td>V</td>
<td>I</td>
</tr>
<tr>
<td>12</td>
<td>21, F</td>
<td>dizziness, lacrimation</td>
<td>partial resection</td>
<td>CPA, IAC, LS, GG, MF</td>
<td>3500</td>
<td>24 12</td>
<td>II</td>
<td>I</td>
</tr>
<tr>
<td>13</td>
<td>17, F</td>
<td>facial palsy</td>
<td>none</td>
<td>GG, MF, TS, MS</td>
<td>5480</td>
<td>24 12</td>
<td>III</td>
<td>I</td>
</tr>
<tr>
<td>14</td>
<td>35, M</td>
<td>facial palsy, hypoacusis, tinnitus, seizure</td>
<td>subtotal resection</td>
<td>CPA, IAC, LS, GG, MF</td>
<td>9280</td>
<td>26 13</td>
<td>II</td>
<td>III†</td>
</tr>
</tbody>
</table>

* CPA = cerebellopontine angle; GG = geniculate ganglion; GR = Gardner-Robertson; IAC = internal auditory canal; LS = labyrinthine segment; MF = middle cranial fossa; MS = mastoid segment; TS = tympanic segment.
† Postoperative effects.

Fig. 1. Case 1. Axial T1-weighted contrast-enhanced MR images obtained before GKS (A), 6 months after GKS (B), and 168 months after GKS (C), demonstrating remarkable shrinkage of facial nerve schwannoma.
Gamma Knife surgery for facial nerve schwannomas

Table 2: Summary of imaging changes after GKS

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Initial (mm³)</th>
<th>At 6 Mos</th>
<th>At Last Follow-Up</th>
<th>Follow-Up (mos)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>10,100</td>
<td>decreased</td>
<td>decreased</td>
<td>170</td>
</tr>
<tr>
<td>2</td>
<td>2800</td>
<td>increased</td>
<td>stable</td>
<td>166</td>
</tr>
<tr>
<td>3</td>
<td>6700</td>
<td>decreased</td>
<td>decreased</td>
<td>127</td>
</tr>
<tr>
<td>4</td>
<td>532</td>
<td>increased</td>
<td>stable</td>
<td>125</td>
</tr>
<tr>
<td>5</td>
<td>153</td>
<td>stable</td>
<td>decreased</td>
<td>99</td>
</tr>
<tr>
<td>6</td>
<td>117</td>
<td>decreased</td>
<td>decreased</td>
<td>96</td>
</tr>
<tr>
<td>7</td>
<td>3200</td>
<td>decreased</td>
<td>decreased</td>
<td>77</td>
</tr>
<tr>
<td>8</td>
<td>367</td>
<td>stable</td>
<td>decreased</td>
<td>72</td>
</tr>
<tr>
<td>9</td>
<td>2500</td>
<td>stable</td>
<td>decreased</td>
<td>67</td>
</tr>
<tr>
<td>10</td>
<td>6600</td>
<td>increased</td>
<td>stable</td>
<td>51</td>
</tr>
<tr>
<td>11</td>
<td>573</td>
<td>increased</td>
<td>decreased</td>
<td>40</td>
</tr>
<tr>
<td>12</td>
<td>3500</td>
<td>increased</td>
<td>stable</td>
<td>32</td>
</tr>
<tr>
<td>13</td>
<td>5480</td>
<td>increased</td>
<td>NP</td>
<td>6</td>
</tr>
<tr>
<td>14</td>
<td>9280</td>
<td>NP</td>
<td>NP</td>
<td>2</td>
</tr>
</tbody>
</table>

*NP = follow-up imaging not performed because of the short follow-up periods.
tion must be considered for patients who experience tumor growth or symptom development. For most patients, partial or subtotal removal yields better facial nerve outcomes than does total removal with nerve grafting, but the long-term risk for recurrence is high. Bony decompression of the facial canal to reduce interfascicular pressure can help improve facial nerve function, but patients need to be assessed regularly for tumor growth. Fascicle preservation surgery that spares the main trunk of the facial nerve is limited to eccentrically growing tumors that involve only a small proportion of nerve fibers; this treatment still carries the risk for damage to the facial nerve.

Because SRS for vestibular schwannomas has been successful, SRS has emerged as a feasible primary treatment option for facial nerve schwannomas. The published studies on SRS for facial nerve schwannomas demonstrate tumor control rates and superior functional outcomes for facial nerve function and hearing comparable to those achieved with microsurgery, although the studies are few and limited by the small number of cases and short follow-up periods (Table 4). In the series reported here, tumor control was good in all 12 patients who were followed up for longer than 2 years, giving a tumor control rate of 100%. A total of 9 patients have been followed up for longer than 5 years and 4 patients for longer than 10 years. The number of cases in our series is small; nevertheless, this time frame is long enough to provide reliable data on long-term tumor control. Of the 14 patients, 11 improved or maintained facial nerve function, and all patients whose hearing was serviceable at baseline maintained this level of hearing after GKS.

For 2 patients in our series, the results of improved facial nerve function were encouraging. For 1 patient, facial palsy improvement was remarkable, from HB Grade V to Grade II. For that patient, the facial palsy had developed abruptly 10 days before the GKS and facial nerve function returned gradually from 3 months after GKS; 1 year after the GKS, facial nerve function was nearly normal. Other than physical therapy, this patient underwent no additional surgery or other treatments for the recovery of facial nerve function. In the studies on SRS for facial nerve schwannoma, several cases demonstrated improved facial nerve function after radiosurgery; some improvement was remarkably good. Unfortunately, the characteristics of those schwannomas for which facial nerve function after radiosurgery was favorable and the mechanism of recovery of facial nerve function are still unknown. We suggest that for the patient in our series for whom facial nerve function improved remarkably, the short period of facial palsy before GKS might have contributed to the recovery of facial nerve function. Gradual recovery of facial nerve function over a long period may be caused by progressive decompression resulting from shrinkage of tumor mass after GKS.

Of the 14 patients in our series, 3 (21.4%) patients experienced deteriorated facial nerve function after GKS. In patients with vestibular schwannomas, the development of facial palsy after GKS is very rare (incidence < 1%) even though the facial nerve is in close proximity to the neoplasm. Considering that the radiosurgery range and marginal dose for vestibular schwannomas and facial nerve

### TABLE 3: Summary of functional and clinical results after GKS

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Facial Nerve Function (HB grade)</th>
<th>Hearing Function (GR class)</th>
<th>New Symptoms</th>
<th>Follow-Up (mos)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>VI</td>
<td>II</td>
<td>none</td>
<td>170</td>
</tr>
<tr>
<td>2</td>
<td>II</td>
<td>I</td>
<td>tinnitus</td>
<td>166</td>
</tr>
<tr>
<td>3</td>
<td>I</td>
<td>V</td>
<td>none</td>
<td>127</td>
</tr>
<tr>
<td>4</td>
<td>II</td>
<td>I</td>
<td>tinnitus</td>
<td>125</td>
</tr>
<tr>
<td>5</td>
<td>III</td>
<td>III</td>
<td>none</td>
<td>99</td>
</tr>
<tr>
<td>6</td>
<td>II</td>
<td>I</td>
<td>none</td>
<td>96</td>
</tr>
<tr>
<td>7</td>
<td>I</td>
<td>V</td>
<td>none</td>
<td>77</td>
</tr>
<tr>
<td>8</td>
<td>IV</td>
<td>V</td>
<td>none</td>
<td>72</td>
</tr>
<tr>
<td>9</td>
<td>II</td>
<td>V</td>
<td>none</td>
<td>67</td>
</tr>
<tr>
<td>10</td>
<td>II</td>
<td>I</td>
<td>none</td>
<td>51</td>
</tr>
<tr>
<td>11</td>
<td>V</td>
<td>I</td>
<td>none</td>
<td>40</td>
</tr>
<tr>
<td>12</td>
<td>II</td>
<td>I</td>
<td>tinnitus</td>
<td>32</td>
</tr>
<tr>
<td>13</td>
<td>III</td>
<td>I</td>
<td>none</td>
<td>6</td>
</tr>
<tr>
<td>14</td>
<td>II</td>
<td>III</td>
<td>none</td>
<td>2</td>
</tr>
</tbody>
</table>

![Fig. 4. Bar graph demonstrating changes in facial nerve function and hearing after GKS.](image-url)
schwannomas are similar, the worsened function after GKS for facial nerve schwannoma seems aberrant. The development of facial palsy after radiosurgery for facial nerve schwannoma might result from mechanical damage to the facial nerve caused by its being pressed against the bony confinement during the temporary period of increased tumor volume (transient edema and expansion) after radiosurgery (Fig. 5). For the patients in our series, worsened facial nerve function developed within 3 months after radiosurgery, whereas the direct radiation injury of cranial nerves attributable to axonal degeneration, demyelination, and ischemia usually results in delayed (longer than 3 months) neuropathy.3 In all 3 patients who experienced deteriorated facial nerve function, the schwannomas involved the segments with bony surroundings and expanded with a loss of central enhancement on MR imaging at 6 months. Although sensory nerves are usually more sensitive to radiation than motor nerves,3,12 we observed mostly stable vestibulocochlear nerve function after radiosurgery for patients with facial nerve schwannoma. This observation indicates that the observed worsening of facial nerve function is attributable to mechanical damage rather than direct radiation injury. Therefore, use of corticosteroids to control edema and expansion during the first several months after radiosurgery might help prevent and alleviate facial palsy.

**Conclusions**

With this series we have shown that GKS is a relatively safe and effective management tool for both newly diagnosed and residual facial nerve schwannomas. Giv-

---

**TABLE 4: Results after microsurgery and radiosurgery for facial nerve schwannomas reported in the literature**

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>No.</th>
<th>Follow-Up (mos)</th>
<th>Functional Outcome</th>
<th>Tumor Size</th>
<th>Tumor Control Rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>microsurgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sherman et al., 2002</td>
<td>9</td>
<td>43.5</td>
<td>3 improved, 4 stable, 2 worsened</td>
<td>1 improved, 6 stable, 2 worsened</td>
<td>8 decreased, 1 increased</td>
</tr>
<tr>
<td>Cornelius et al., 2008</td>
<td>10</td>
<td>61.2</td>
<td>1 improved, 3 stable, 6 worsened</td>
<td>9 stable, 1 worsened</td>
<td>8 decreased, 2 increased</td>
</tr>
<tr>
<td>Jacob et al., 2012</td>
<td>7</td>
<td>48</td>
<td>2 improved, 1 stable, 4 worsened</td>
<td>5 stable, 1 worsened</td>
<td>7 decreased</td>
</tr>
<tr>
<td>radiosurgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kida et al., 2007</td>
<td>14</td>
<td>31.4</td>
<td>5 improved, 8 stable, 1 worsened</td>
<td>14 stable</td>
<td>8 decreased, 6 stable</td>
</tr>
<tr>
<td>Litre et al., 2007</td>
<td>11</td>
<td>39</td>
<td>3 improved, 8 stable</td>
<td>11 stable</td>
<td>4 decreased, 6 stable, 1 increased</td>
</tr>
<tr>
<td>Madhok et al., 2009</td>
<td>6</td>
<td>46.6</td>
<td>1 improved, 5 stable</td>
<td>6 stable</td>
<td>3 decreased, 3 stable</td>
</tr>
<tr>
<td>Jacob et al., 2012</td>
<td>6</td>
<td>48</td>
<td>4 stable, 2 worsened</td>
<td>2 stable, 1 worsened</td>
<td>5 stable, 1 increased</td>
</tr>
<tr>
<td>present study</td>
<td>14</td>
<td>80.7</td>
<td>2 improved, 9 stable, 3 worsened</td>
<td>13 stable, 1 worsened</td>
<td>7 decreased, 5 stable</td>
</tr>
</tbody>
</table>

![Fig. 5. Schematic diagrams illustrating the mechanism of facial nerve damage after GKS for facial nerve schwannoma. Before GKS, the facial nerve schwannoma involves the labyrinthine segment and the geniculate ganglion and is surrounded by bony structures (left). During the temporary period of increased tumor volume caused by transient postradiosurgical edema and expansion, the facial nerve is damaged by pressure against the bony confinement (right). Copyright Ju Hyung Moon. Published with permission.](image-url)
en the excellent long-term tumor control and functional outcomes, GKS might be a good primary treatment option for patients with small- to mid-sized facial nerve schwannoma when facial nerve function and hearing are relatively preserved. Larger studies with longer follow-up periods are needed to define optimal radiosurgical strategies and to evaluate long-term outcomes.

Disclosure

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author contributions to the study and manuscript preparation include the following. Conception and design: JH Chang. Acquisition of data: Moon. Analysis and interpretation of data: Moon. Drafting the article: Moon. Critically revising the article: JH Chang. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: JH Chang. Administrative/technical/material support: JH Chang, WS Chang, Jung, Lee, Park. Study supervision: JH Chang.

References


Manuscript submitted June 30, 2014.
Accepted August 4, 2014.

Please include this information when citing this paper: DOI: 10.3171/2014.8.GKS141504.

Address correspondence to: Jong Hee Chang, M.D., Ph.D., Department of Neurosurgery, Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of Korea. email: changjh@yuhs.ac.